Berry Genomics Co. Ltd. Class A
SSZSE:0007109.85
CNY
-0.11
(-1.10%)
ISIN
CNE000000PN7
Return %
Stock
S&P 500
1Y
-23.47
13.14
3Y
6.49
80.78
5Y
-51.17
67.74
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Yang Gao
- Full Time Employees
- 1,331
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Building 5 Beijing BE China 102206
- IPO Date
- Apr 22, 1997
- Website
- berrygenomics.com
- Similar Companies
- Business
- Berry Genomics Co., Ltd, founded in 2010 and headquartered in Beijing, China, is a leading clinical genomics and life sciences company specializing in the development and commercialization of genetic test technologies for clinical applications. The company provides a comprehensive range of genetic testing services and products, including non-invasive prenatal testing (NIPT), genetic disease testing, tumor genetic testing, and sequencing platforms such as the NextSeq CN500 and the Sequel II CNDx. Berry Genomics also offers laboratory solutions, reagent sales—covering DNA extraction, purification, library preparation, and sequencing reagents—and genetic sequencing equipment sales. The company serves over 6000 institutions including hospitals, research institutions, universities, and corporations across China, Hong Kong, Macao, Taiwan, Southeast Asia, the Middle East, and Australia. Its business segments encompass basic scientific research, clinical testing services, and medical device manufacturing, with a strong focus on reproductive health, oncology, and genetic disease detection. Recently, Berry Genomics has made significant operational advancements with the strategic delivery and integration of Pacific Biosciences' Vega long-read sequencing systems, marking a key advancement in their genomic service capabilities aimed at enhancing genetic carrier, prenatal, and newborn screening programs. The company is actively localizing testing reagents for these platforms and has secured regulatory approvals for their sequencing technologies, including the first worldwide authorization to deploy long-read sequencing in clinical settings. Berry Genomics has also launched the GENOisi™ intelligent agent, an AI-powered tool designed to enhance obstetric and pediatric screening at county-level healthcare providers, establishing a three-tiered health management system covering primary screening, regional diagnosis, and national research. This strategic shift emphasizes expansion into precision medicine and AI-assisted clinical genomics, aiming for broader market penetration domestically and internationally. The company continues to invest heavily in R&D, particularly in second- and third-generation sequencing technologies, driving innovation in gene sequencing accuracy, with a robust portfolio of patented core technologies integrated into their product offerings. Berry Genomics operates seven certified clinical laboratories located in key Chinese cities including Beijing, Shanghai, Chengdu, Chongqing, Qingdao, Fuzhou, and Hong Kong. It is recognized for its comprehensive approach, covering the entire genomics workflow from equipment to data interpretation and clinical report delivery. The company remains focused on innovation, quality, and expanding the use of advanced sequencing technologies such as single-molecule real-time sequencing and high-fidelity long-read sequencing to improve diagnostic accuracy across a range of genetic and oncological conditions. Berry Genomics continues to drive technological leadership in China's expanding genomic market with a strong presence in reproductive genetics, cancer early detection, and genomic data services while expanding its influence into global markets through strategic alliances and technology transfers. The company’s continuous growth is supported by its strategic alliance with Singleron Biotechnologies in single-cell sequencing and its commitment to integrating third-generation sequencing technology into clinical practice, positioning Berry Genomics as a top-tier partner in genomics innovation. It employs approximately 1500 staff dedicated to R&D, clinical service, and market development. Listed on the Shenzhen A-share market since 2017 under ticker 000710.SZ, Berry Genomics is a pivotal player in advancing clinical genomics technology in China and beyond.